Guiyang Xintian Pharmaceutical: Notice on obtaining a trademark registration certificate
Xintian Pharmaceutical: Announcement on Further Explanation of the 2023 Profit Distribution Plan
Xintian Pharmaceutical: Comparative Table of Amendments to the Articles of Association
Xintian Pharmaceutical: Report of the Board of Directors on the evaluation of the performance of accounting firms in 2023 and the performance of supervisory duties by the Audit Committee
Xintian Pharmaceutical: Announcement on Hiring a 2024 Financial and Internal Control Auditor
Xintian Pharmaceutical: Internal Control Self-Assessment Report
Xintian Pharmaceutical: Announcement on Organizational Structure Adjustments
Xintian Pharmaceutical: Notice of Annual General Meeting of Shareholders
Xintian Pharmaceutical: Announcement on holding an online briefing on the 2023 annual results
Xintian Pharmaceutical: Announcement on the Resignation of Deputy General Manager
Xintian Pharmaceutical: Announcement on the conversion of convertible corporate bonds to shares in the first quarter of 2024
Xintian Pharmaceutical: Announcement on foreign investment to establish wholly-owned subsidiaries and complete industrial and commercial registration
Xintian Pharmaceutical: Announcement on Abnormal Stock Trading Fluctuations and Risk Alerts
Xintian Pharmaceutical: Announcement on Abnormal Fluctuations in Xintian Bond Transfer Transactions
Xintian Pharmaceutical: Instructions of the board of directors that this restructuring complies with the provisions of Articles 11 and 43 of the “Administrative Measures on Major Asset Reorganization of Listed Companies”
Xintian Pharmaceutical: Explanation of the confidentiality measures and confidentiality system adopted by the board of directors on this major asset restructuring
Xintian Pharmaceutical: Announcement on the resumption of trading of the company's shares, the resumption of trading of convertible corporate bonds, and the conversion of shares
Xintian Pharmaceutical: Explanation of the Board of Directors on the purchase and sale of assets within 12 months prior to the restructuring
Xintian Pharmaceutical: Explanation of the board of directors on the completeness and compliance of the legal procedures and the validity of the submitted legal documents in this restructuring
Xintian Pharmaceutical: Announcement on the shareholding information of the top ten shareholders on the previous trading day before issuing shares to purchase assets and related transactions were suspended
No Data